Key points are not available for this paper at this time.
Introduction: Addressing the challenges in diabetic foot ulcer (DFU) management is critical, given the high morbidity, mortality, and healthcare costs associated with this devastating complication of diabetes. This study introduces an innovative strategy for DFU risk stratification using Electrochemical Skin Conductance (ESC) measurements from the Sudoscan device. It is a quick, non-invasive, painless, reproducible technique that does not require fasting or stopping treatment. Methods: The study involved 2157 diabetic patients from four French hospitals, evaluating the association between ESC measures and DFU risk stratification scores based on 10g monofilament testing. Results: Multivariate analysis affirmed the association, independently of others covariate (age, sex), between the ESC and the DFU grades. ROC curve analysis demonstrated good predictive power for DFU grades 3, 2, and 1 (AUC=0.82/0.62/0.62.) but revealed limitations for grade 0 (AUC=0.34) due to the wide range of ESC values. Heatmap analysis showcased ESC's granularity within low-grade patients, suggesting potential subgroups not captured by the standard grading system. Conclusion: With a quantifiable association between ESC measures and high DFU grades while revealing differences for low DFU grade, this approach offers an avenue for improving precision in risk assessment at early and reversible diabetic peripheral neuropathy stages therefore fostering early clinical intervention. Healthcare Equity: The standardized and objective nature of ESC measurements while having a low cost contributes to more equitable healthcare delivery. By reducing disparities in risk identification, this approach ensures consistent and accurate assessments, regardless of geographical location or healthcare provider. Disclosure B. Vittrant: Employee; Withings. J. Gautier: Board Member; Sanofi. Other Relationship; Sanofi. Speaker's Bureau; AstraZeneca, Novo Nordisk. Research Support; Novo Nordisk. Advisory Panel; Pfizer Inc. J. Riveline: Board Member; Abbott, Novo Nordisk A/S, Sanofi, Eli Lilly and Company, Medtronic, Dexcom, Inc., Insulet Corporation, Air Liquide, AstraZeneca. L. Potier: Research Support; Abbott. Consultant; AstraZeneca, Bayer Inc., Eli Lilly and Company, Novo Nordisk, Sanofi, Boehringer-Ingelheim. O. Bourron: Speaker's Bureau; Novo Nordisk, Sanofi, Lilly Diabetes, AstraZeneca, Bayer Inc. Research Support; Withings. P. Brunswick: Consultant; Impeto medical. B. Bauduceau: Consultant; Lilly Diabetes, Boehringer-Ingelheim, AstraZeneca. A. Criton: Employee; Withings.
Vittrant et al. (Fri,) studied this question.